Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2017 | 2 |
2020 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z.
Trials. 2017.
PMID: 28270164
Free PMC article.
Clinical Trial.
Recently, the development of an ointment containing a TRK inhibitor (pegcantratinib - previously CT327 - from Creabilis SA) allowed for the assessment of TRK inhibition in tumours from patients with inherited CYLD mutations. ...
Recently, the development of an ointment containing a TRK inhibitor (pegcantratinib - previously CT327 - from Creabilis SA) allowed f …
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B, Trower M, Duggal A, Guglielmini P, Harris P, Jackson D, Lacouture ME, Ratti E, Tonini G, Wood A, Ständer S.
Vincenzi B, et al.
BMJ Open. 2020 Feb 6;10(2):e030114. doi: 10.1136/bmjopen-2019-030114.
BMJ Open. 2020.
PMID: 32034016
Free PMC article.
Clinical Trial.
Item in Clipboard
Development and validation of LC-MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors.
Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ.
Zangarini M, et al.
Bioanalysis. 2017 Feb;9(3):279-288. doi: 10.4155/bio-2016-0199. Epub 2017 Jan 23.
Bioanalysis. 2017.
PMID: 28111963
Free PMC article.
Item in Clipboard
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, Wickramasinghe R, Anand U, Anand P.
Roblin D, et al.
Acta Derm Venereol. 2015 May;95(5):542-8. doi: 10.2340/00015555-2047.
Acta Derm Venereol. 2015.
PMID: 25594427
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite